Abstract: The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-B expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-B inhibitors with ionizing radiation to treat cancer patients.
Abstract: The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as detection antibody) and mAb 16-2C9C3 (as capture antibody) in human urine are provided herein. Specifically, the ELISA assay utilizes a capture mAb and a detection mAb to yield a high sensitivity of <50 ng/mL. The presence of DEK in urine is useful in predicting or diagnosing the occurrence of bladder cancer in humans.
Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to a combination of anti-immune checkpoint and anti-angiogenesis therapies.
Abstract: An antibody comprising an antigen recognition domain exhibiting species cross reactivity to human QSOX1 and murine QSOX1 is disclosed. Methods of producing the antibody, pharmaceutical compositions comprising the antibody and methods of using the antibody for treating medical conditions are also disclosed.
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
May 29, 2020
Date of Patent:
November 10, 2020
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Colette Song, Linus Backert, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
May 29, 2020
Date of Patent:
November 10, 2020
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.
Type:
Grant
Filed:
November 12, 2015
Date of Patent:
October 20, 2020
Assignee:
Probiocon GmbH
Inventors:
Helmut Salih, Ludger Grosse-Hovest, Andreas Herrmann, Hans-Georg Kopp, Stefanie Maurer
Abstract: A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.
Type:
Grant
Filed:
December 18, 2015
Date of Patent:
October 13, 2020
Assignee:
CytomX Therapeutics, Inc.
Inventors:
Herman Waldmann, Mark Raymond Frewin, Lisa Kim Gilliland, Luis Richardo Simoes Da Silva Graca
Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
Type:
Grant
Filed:
July 27, 2015
Date of Patent:
September 29, 2020
Assignee:
Novartis AG
Inventors:
Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
Abstract: Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.
Type:
Grant
Filed:
December 15, 2017
Date of Patent:
September 29, 2020
Assignee:
DANA-FARBER CANCER INSTITUTE, INC.
Inventors:
Levi A. Garraway, Caroline Emery, Nikhil Wagle
Abstract: The present disclosure relates to conjugates, preferably, antibody-drug conjugates, directed against select non-transmembrane tumor antigens that are normally intracellular but can be secreted from cancer cells, such as human cathepsin D, and can be targeted in a way that enables the selective delivery of the conjugate to cancer cells. The design and mechanism of action disclosed enable the preferential delivery of the conjugate prodrug to cancer cells over normal cells for the purpose of selectively killing cancer cells. The uses of such conjugates for the treatment of cancer are described.
Abstract: The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.
Abstract: Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.
Type:
Grant
Filed:
October 17, 2017
Date of Patent:
September 22, 2020
Assignee:
Wayne State University
Inventors:
Michael Tainsky, Madhumita Chatterjee, Gregory Dyson, Nancy Levin
Abstract: Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4-1BB antibody, where said features may improve certain characteristics of the antibody relative to a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFN?, as well as detection, prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof.
Type:
Grant
Filed:
February 13, 2020
Date of Patent:
September 15, 2020
Assignee:
Eutilex Co., Ltd.
Inventors:
Byoung S. Kwon, Seoung-Joo Lee, Young Ho Kim, Ho-Sik Oh, Joong Won Lee
Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for FZD7, which preferably do not substantially interact with (bind to) other FZD family members, and methods of making said anti-FZD7 antibodies and binding fragments thereof. Another embodiment relates to antibodies and binding fragments comprising sequences of VH, VL and/or CDR polypeptides described herein. The invention also contemplates conjugates of anti-FZD7 antibodies and binding fragments. The invention further contemplates use of anti-FZD7 antibodies and binding fragments for tissue engineering. This invention also relates to a transgenic mouse expressing the epitope of anti-FZD7 antibodies and binding fragments thereof. Embodiments also pertain to use of anti-FZD7 antibodies and binding fragments (as well as the identified FZD7 epitope) for diagnosis, assessment, prevention and/or treatment of diseases and disorders associated with aberrant FZD7 expression, such as cancer.
Type:
Grant
Filed:
June 16, 2016
Date of Patent:
September 8, 2020
Assignee:
The Regents of the University of California
Abstract: It has now been discovered that activated lymphocyte cell adhesion molecule (ALCAM)—also known as CD166—is the ligand of the innate immune receptor ILT3 that is expressed by DC and monocytes. It has been further discovered that the specific binding of ILT3 to its ligand CD166 on the surface of CD166-expressing cancer cells, arrested cancer cell growth and initiated apoptosis. Therefore, certain embodiments relate to methods and compositions for treating CD166-expressing cancers by administering ILT3Fc, full-length ILT3 or any CD166 ligand-binding fragment thereof.
Type:
Grant
Filed:
July 18, 2016
Date of Patent:
September 8, 2020
Assignee:
The Trustees of Columbia University in the City of New York
Inventors:
Nicole Suciu-Foca, George Vlad, Zheng Xu
Abstract: The present invention is directed to claudin-1-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or cancer cells using the peptide reagents.
Type:
Grant
Filed:
February 25, 2016
Date of Patent:
August 18, 2020
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors:
Thomas D. Wang, Emily Rabinsky, Bishnu P. Joshi
Abstract: Provided herein are compositions, methods and uses involving antibodies that bind to ErbB, a receptor tyrosine kinase, and modulate the activity of ErbB. Also provided are uses and methods for treating disorders, such as cancer, by administering to subject an antibody that binds to ErbB.
Type:
Grant
Filed:
April 10, 2015
Date of Patent:
August 18, 2020
Assignees:
Celldex Therapeutics, Inc., Yale University
Inventors:
Joseph Schlessinger, Diego Alvarado, Sangwon Lee
Abstract: Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.
Type:
Grant
Filed:
December 2, 2015
Date of Patent:
August 18, 2020
Assignees:
THE UNIVERSITY OF TOKYO, IDAC THERANOSTICS, INC.
Abstract: The present invention provides a purified antibody that recognizes the conserved zinc fingers linker region (ZnFL) in multiple KRAB-ZNF. The purified antibody recognizes at least one of a conserved zinc finger linker sequence of TGEKPY (SEQ ID NO: 1), TGEKPYK (SEQ ID NO: 2), and TGEKPYE (SEQ ID NO: 3). A method of treating a patient having cancer comprising administering an effective amount of a purified antibody recognizing at least one of a conserved zinc finger linker sequence of TGEKPY (SEQ ID NO: 1), TGEKPYK (SEQ ID NO: 2), and TGEKPYE (SEQ ID NO: 3) is set forth. A diagnostic kit and an affinity matrix detecting one of these conserved zinc finger linker sequences are disclosed. A method of detecting cancerous cells comprising subjecting a cancerous cell to a purified pan-ZNF specific antibody is provided.